Respiratory syncytial virus (RSV) is the most common respiratory virus to cause infection after allogeneic hematopoietic stem cell transplantation (HSCT). RSV infection progresses to lower respiratory tract infection in 40%-50% of RSV-infected patients. RSV-associated pneumonia was reported to be associated with fatal outcome for more than one-half patients [1] . Although some observations indicate that early treatment of RSV infection with aerosolized ribavirin and/or hyperimmune globulin may prevent progression of disease, no definitive proof of efficacy is available for this patient population [1] [2] [3] [4] [5] . Moreover, aerosolized ribavirin cannot be used in most French hospitals because it is considered to be potentially dangerous for caretakers, and hyperimmune g-globulins are not available in France. Palivizumab, an RSV-specific monoclonal antibody, has been shown to significantly reduce the RSV load in pulmonary tissue in murine models and to lower rates of RSV infectionrelated hospitalization for high-risk infants after monthly prophylaxis [6, 7] . A phase 1 study of allogeneic and autologous HSCT recipients found that stable, effective serum levels of palivizumab were maintained for 21 days, no adverse events occurred, and no anti-palivizumab antibody response occurred [8] . Since the time of that publication, palivizumab has been used in an uncontrolled manner to treat RSV infection in HSCT recipients, including those in our transplant unit, with no clear understanding of its impact on outcome. This study was conducted to estimate the impact of palivizumab treatment, if any, on prevention of progression from upper to lower respiratory tract infection and on the overall mortality rate among HSCT recipients with RSV infection.
Among 40 allogeneic stem cell transplant recipients who developed symptomatic respiratory syncytial virus infection, including 22 patients with lower respiratory tract infection, 19 received palivizumab (9 of whom had upper respiratory tract disease). Palivizumab did not prevent progression to lower respiratory infection and had no impact on the overall survival rate.
Respiratory syncytial virus (RSV) is the most common respiratory virus to cause infection after allogeneic hematopoietic stem cell transplantation (HSCT). RSV infection progresses to lower respiratory tract infection in 40%-50% of RSV-infected patients. RSV-associated pneumonia was reported to be associated with fatal outcome for more than one-half patients [1] . Although some observations indicate that early treatment of RSV infection with aerosolized ribavirin and/or hyperimmune globulin may prevent progression of disease, no definitive proof of efficacy is available for this patient population [1] [2] [3] [4] [5] . Moreover, aerosolized ribavirin cannot be used in most French hospitals because it is considered to be potentially dangerous for caretakers, and hyperimmune g-globulins are not available in France. Palivizumab, an RSV-specific monoclonal antibody, has been shown to significantly reduce the RSV load in pulmonary tissue in murine models and to lower rates of RSV infectionrelated hospitalization for high-risk infants after monthly prophylaxis [6, 7] . A phase 1 study of allogeneic and autologous HSCT recipients found that stable, effective serum levels of palivizumab were maintained for 21 days, no adverse events occurred, and no anti-palivizumab antibody response occurred [8] . Since the time of that publication, palivizumab has been used in an uncontrolled manner to treat RSV infection in HSCT recipients, including those in our transplant unit, with no clear understanding of its impact on outcome. This study was conducted to estimate the impact of palivizumab treatment, if any, on prevention of progression from upper to lower respiratory tract infection and on the overall mortality rate among HSCT recipients with RSV infection.
Materials and methods. We retrospectively reviewed the charts for all patients who had undergone allogeneic HSCT at our institution and who received a diagnosis of RSV infection during the period from January 1999 through March 2006. Infections were diagnosed by immunofluorescence detection of RSV antigen in nasopharyngeal aspirate and/or bronchoalveolar lavage fluid specimens. Lower respiratory tract infections were defined as radiographic pulmonary abnormalities in patients with signs and symptoms (e.g., cough, dyspnea, sputum production, and fever) [9] . The first patient received palivizumab in December 2001. Thereafter, the decision regarding whether to prescribe palivizumab was left to the discretion of the treating physician.
Results of variables tested are reported as numbers of patients or median values and ranges. Groups of patients treated with palivizumab and those who were not treated with palivizumab were compared using the Wilcoxon rank sum test for continuous covariates; the x 2 test or Fisher's exact test was used to compare categorical covariates. Survival after the diagnosis of RSV infection was defined as the time that elapsed between the diagnosis of RSV infection and the last follow-up visit. To avoid time-dependent bias, survival of patients treated with palivizumab was counted from date of treatment instead of the date of diagnosis of RSV infection. The Kaplan-Meier method was used to estimate survival. Potential factors prognostic of survival were tested using Cox proportional hazards models or log rank tests, and the model that best predicted survival was selected on the basis of Akaike's model selection criterion. Tests were 2-sided, with the statistical significance level set at .05. Analyses were conducted using the R statistical package (The R Foundation for Statistical Computing). Survival results are presented as estimates and 95% CIs. 6 (67) 9 (75) 6 (60) 25 (63) Nonmalignancies 3 (33)
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0 (0) 1 (8) 2 (20) 6 ( 8 (89) 1 (8) 3 (30) 15 ( Results. During the period from January 1999 through March 2006, a total of 40 patients who had developed symptomatic RSV infection were identified. Characteristics of the patients and of their infections are summarized in table 1. Twenty-five patients (62%) had received a stem cell graft transplant from an unrelated donor. The median interval from transplantation to diagnosis of RSV infection was 85 days. Four patients started to shed RSV before they underwent HSCT. RSV infection occurred mostly in young patients (median age, 16 years), 150% of whom had lower respiratory tract involvement at the time of diagnosis, and 6 patients required oxygen therapy at the time of diagnosis.
Nineteen patients received intravenous palivizumab at a dosage of 15 mg/kg for 1-3 injections per month (median, 1 injection per month), according to the duration of RSV shedding and clinical symptoms. The median cost of palivizumab therapy per patient was US$8145. No adverse reactions were recorded. Palivizumab was initiated a median of 2 days after the diagnosis of RSV infection. Patients treated with palivizumab differed significantly from those who were not treated with palivizumab with regard to whether the source of cord blood was unrelated, the median neutrophil count at the time of diagnosis of RSV infection, and the interval between HSCT and diagnosis of RSV infection (
). There was a trend to lower lymphocyte P ! .05 counts in palivizumab-treated patients ( ). P p .08 Palivizumab did not prevent progression from upper to lower respiratory tract infection; 56% of patients in both groups had progression to lower respiratory tract infection. None of the other tested variables (i.e., age, cytomegalovirus infection status of the recipient, source of stem cells, interval between transplantation and diagnosis of RSV infection, neutrophil and lymphocyte count, presence of moderate-to-severe or extensive chronic graft-versus-host disease, prednisolone dose, and whether intravenous ribavirin was administered) were predictive of progression to lower respiratory tract infection.
The 1-year overall rate of survival was 76% (95% CI, 63%-91%). There was no significant difference in the survival rate between patients with upper respiratory tract infection and those with lower respiratory tract infection, regardless of whether the patients received palivizumab ( ) (figure P p .71 1A). Palivizumab use had no impact on the patient survival rate, regardless of the type of RSV infection. Given this evidence and the limited number of patients and events, we examined prognostic factors for mortality, for the entire sample, at 3 months after the diagnosis of RSV infection (the last death of a patient with ongoing RSV infection occurred on day 84 after diagnosis). Only oxygen requirement at diagnosis (hazard ratio, 3.2; 95% CI, 0.6-16.8;
) and receipt of cord blood from P p .08 an unrelated donor (hazard ratio, 5.9; 95% CI, 1.3-27.1;
) were independently associated with mortality. Figure  P p .02 1B presents the 3-month survival data for the 26 patients with neither of these 2 factors, compared with the data for the 14 patients who had one or both risk factors ( ). Age, type P p .02 and status of underlying disease, recipient cytomegalovirus status, interval from transplantation to RSV infection, lymphocyte and neutrophil count, moderate-to-severe acute or extensive chronic graft-versus-host disease at diagnosis of RSV infection, upper versus lower respiratory tract RSV infection, steroid dose at diagnosis of RSV infection, intravenous ribavirin treatment, and palivizumab therapy had no impact on the 3-month mortality rate. During the year after diagnosis of RSV infection, 9 patients died (table 1); all of these patients were recipients of a transplant from an unrelated donor, including 4 recipients of cord blood from unrelated donors. Two patients died of relapsed primary hematological disease (RSV infection was present at the time of death for one of these patients), and 1 patient died of acute graft-versus-host disease and bacterial sepsis. Only 1 patient died of RSV pneumonia alone; this death occurred on day 78 after diagnosis of RSV infection. This patient had received a cord blood transplant from an unrelated donor and had an initial upper respiratory tract infection and subsequent RSV pneumonia, despite having received 3 palivizumab injections. Five other deaths were caused by multiplecause respiratory failure (invasive aspergillosis, disseminated adenovirus disease, influenza, or bacterial sepsis), with RSV infection noted as an associated cause for 3 patients. Of note, the 5 patients with upper respiratory tract infection who died had experienced progression to lower respiratory disease before death, even though the primary cause of death was hematological relapse for 2 of them.
Discussion. To the best of our knowledge, here we describe the largest single-center population of allogeneic HSCT recipients with RSV infection. Most patients were adolescents, and one-half of them had signs of lower respiratory tract infection at diagnosis of RSV infection, as has been found in previous reports [1, 10] . The 1-year overall survival rate was 76%, which is consistent with recently published data [2, 4, 5, 10] .
On the basis of our analysis, we found that palivizumab had no impact on outcome, as assessed by progression to lower respiratory tract infection, early mortality rate, and 1-year overall survival rate. Similarly, clinical outcomes for 21 placebotreated and 22 palivizumab-treated (15 mg/kg) immunocompetent children with RSV infection did not differ significantly; serum palivizumab concentrations remained satisfactory [11] . Palivizumab is licensed for RSV prophylaxis in high-risk children, and no definitive proof of activity against RSV disease has been published. It is likely that, at the time of diagnosis, RSV replication has already been ongoing for several days and that RSV infection/disease may also result from a pathogenic immune response [12, 13] .
Lower upper respiratory tract infection (as opposed to upper respiratory tract infection) is a well-known risk factor for RSVassociated mortality in HSCT recipients [1, 14] . The need for oxygen therapy at diagnosis of RSV infection can be considered a marker of advanced lower respiratory tract infection and adds some precision to this criterion. Finally, receipt of a cord blood transplant from an unrelated donor, which generates notably slower immune reconstitution [15] , was independently associated with an adverse outcome in our study; to our knowledge, this has not been described previously .
Of course, we recognize that no robust evaluation of the impact of palivizumab treatment on outcome can be made here, because palivizumab was sometimes given to patients with classic indicators of a poorer prognosis (i.e., infection was diagnosed soon after HSCT, and the patients had lower neutrophil and lymphocyte counts) [1, 2] . However, we did not find any support for the use of palivizumab after allogeneic HSCT, although we concede that we did not monitor the patients' RSV loads. Given the high cost of palivizumab therapy and the availability of several new compounds, our findings do not support further use of this drug in an uncontrolled manner.
